ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 20...( PARIS March 4 /- 2008 Key ...)

    PARIS, March 4 /PRNewswire-FirstCall/ --

    2008 Key milestones
    - Strong R&D investments, especially in EHT Dx21 and EHT 0202 clinical
      programs:
      - Recruitment of 311 samples achieved for EHT Dx21
      - Start of Phase IIa for EHT 0202 in Alzheimer's disease
    - Expansion of the strategic collaboration with Allergan and extension
      until end 2011

    2008 Key events
    - Appointment of a new Management Board
    - New positioning of Genomic Services and of the SpliceArray(TM) product
      line
    - Repositioning compounds from existing programs to new therapeutic
      indications
    - Issuance of warrants with an exercise period through June 2009

    2009 Outlook
    - Transformation into an emerging healthcare player from an R&D driven
      organization
    - EHT 0202 Phase IIa results available in Q4 2009
    - Expanding EHT 202 program to other CNS indications
    - Initiation of epitope discovery programs for ocular disorders with
      Allergan
    - Preparing for first product launch with EHT Dx21 in Q4 2009
    - Supply of refined biomarker signatures to bioMerieux



    Key figures

                                                 2008          2007
                                             (million EUR) (million EUR)

    Total revenues                                4.2           5.4
    R&D expenses                                  9.9           8.6
    Operating result                            (11.4)         (7.8)
    Net result                                   (8.9)         (7.3)
    Cash burn from operations                     9.6           4.9
    Consolidated cash & cash equivalents at
    Dec. 31                                      21.0          31.3

ExonHit Therapeutics (Alternext: ALEHT) today announced its consolidated financial results for the year ending December 31, 2008.

"2008 was a year of transfor
'/>"/>